The most useful cannabis research is often less dramatic than the claims surrounding it.
The newly published protocol for the RESONANCE trial does not set out to prove that cannabis treats a tumour. It asks whether a carefully studied medicinal-cannabis formulation can improve quality of life and symptom control for people living with advanced cancer.
That distinction matters. Patients are already using cannabis for pain, nausea, appetite, anxiety and sleep. What clinicians still lack is enough high-quality evidence to predict who benefits, at what dose, with which adverse effects and at what cost.
Published online in Clinical Therapeutics on 20 July 2026, the protocol describes a phase I/II multicentre study in Australia. It is an important addition to the evidence base. It is also only a protocol: no efficacy result has been reported.
What the trial is designed to do
The first phase is open-label. Researchers will examine safety, tolerability, clinical outcomes and how the investigational medicine moves through the body.
The second phase is double-blind and randomised. Participants receive medicinal cannabis or placebo, while researchers assess quality of life and a broad set of symptoms: pain, loss of appetite, anxiety, sleep problems and nausea. Treatment satisfaction, toxicity and caregiver burden are also included.
The Australian trial registry describes an oral oil that begins once daily and can be increased, with two-thirds of participants allocated to medicinal cannabis and one-third to placebo. The registered study is recruiting adults with incurable advanced cancer in Victoria.
That design does something observational reports cannot. A placebo group and blinded allocation help separate a treatment effect from expectation, natural symptom fluctuation and changes in the rest of a person’s care.
The phase I component is equally valuable. In palliative care, “Does it work?” cannot be separated from “Can this person tolerate it?” Sedation, dizziness, cognitive effects and drug interactions can outweigh a modest improvement, particularly for people already taking several medicines.
What the protocol does not show
A protocol is the plan for a study. Publication allows other researchers and clinicians to inspect the question, design and outcomes before the findings are known. That transparency reduces the temptation to redefine success after seeing the data.
It does not show that medicinal cannabis has improved a single participant’s symptoms. It does not establish an effective dose. It does not demonstrate that cannabis slows cancer or changes survival.
The trial’s focus is supportive care. Conflating symptom control with anti-cancer treatment would misrepresent both the research and the choices patients face. Anyone using cannabis alongside chemotherapy, immunotherapy or another treatment should discuss it with their oncology team because interactions and side effects are clinically relevant.
Our wider guide to medical cannabis and cancer explains the difference between symptom evidence and anti-tumour claims.
Why the result cannot be assumed
There is a tendency to treat every new cannabis trial as a delayed confirmation of what advocates already believe. The existing controlled evidence does not support that confidence.
A separate double-blind Australian study, published in 2025, tested a 1:1 THC:CBD oil alongside specialist palliative care in advanced cancer. It found the oil was no better than palliative care alone for the symptoms studied. Adverse events were more common in the cannabinoid group.
That does not make RESONANCE unnecessary. It makes the new study more necessary. Formulation, dose, eligibility criteria, outcome choice and study duration can all affect a result. Replication and well-designed disagreement are how a credible evidence base develops.
RESONANCE also includes outcomes that patients and families recognise as connected. Pain, sleep, appetite, anxiety and caregiver burden do not arrive in separate boxes. Measuring them together may provide a more realistic view of whether treatment changes daily life.
Why UK patients should pay attention
The study is Australian, but the uncertainty it addresses is central to the British debate.
UK cannabis-based products for medicinal use can be prescribed, yet routine NHS access remains extremely limited. One reason is the gap between widespread real-world use and the kind of comparative evidence required for clinical guidance and public funding.
Private prescribing can produce useful observational data, but it cannot replace randomised evidence. At the same time, a narrow insistence on one outcome can miss what matters in palliative care. A medicine may be worthwhile because a person eats more comfortably, sleeps better or relies less on another poorly tolerated drug, even if it does not transform a single pain score.
The trial’s emphasis on quality of life is therefore welcome. The eventual analysis will still need to report absolute differences, adverse effects, withdrawals and uncertainty—not simply whether one statistical threshold was crossed.
Questions to ask when results arrive
When RESONANCE reports, five questions will matter.
How many people completed each phase, and why did others withdraw? What formulation and dose did participants actually tolerate? How large was any improvement compared with placebo, not merely whether it was statistically significant? Which adverse effects occurred, and how often? Were benefits spread across the group or concentrated in a smaller subgroup?
Caregiver burden deserves equal attention. An intervention that modestly eases one symptom but increases confusion, falls risk or supervision needs may not improve the household’s overall experience.
Longer-term follow-up will matter too. The protocol can produce a stronger short-term answer, but advanced cancer is not one diagnosis and symptom patterns change with disease and treatment.
The editorial view
RESONANCE is valuable because it replaces a broad claim with a testable question.
For patients, that may feel slower than the certainty offered by commercial marketing or viral testimony. It is also more respectful. People with advanced cancer deserve evidence that acknowledges urgency without exploiting it.
The responsible headline is not that cannabis has been proved to improve cancer care. It is that researchers are conducting the kind of blinded, patient-centred trial needed to find out. The result—positive, negative or mixed—will be the story.
Key takeaways
- RESONANCE is a phase I/II multicentre trial in advanced cancer.
- Phase I examines safety, tolerability and pharmacokinetics; phase II is randomised, double-blind and placebo-controlled.
- Outcomes include quality of life, pain, appetite, anxiety, sleep, nausea, toxicity and caregiver burden.
- The July publication is a protocol, not evidence that the treatment works.
- The study concerns symptom control and supportive care, not whether cannabis treats cancer itself.
